Compare SCYX & GAUZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCYX | GAUZ |
|---|---|---|
| Founded | 1999 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.3M | 22.5M |
| IPO Year | 2014 | 2024 |
| Metric | SCYX | GAUZ |
|---|---|---|
| Price | $0.67 | $0.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $3.00 | ★ $11.50 |
| AVG Volume (30 Days) | 408.0K | ★ 421.6K |
| Earning Date | 11-05-2025 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,932,000.00 | ★ $96,810,000.00 |
| Revenue This Year | $167.73 | $22.59 |
| Revenue Next Year | $290.78 | $47.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 7.87 |
| 52 Week Low | $0.57 | $0.95 |
| 52 Week High | $1.31 | $13.00 |
| Indicator | SCYX | GAUZ |
|---|---|---|
| Relative Strength Index (RSI) | 59.59 | 33.86 |
| Support Level | $0.58 | $1.17 |
| Resistance Level | $0.64 | $1.39 |
| Average True Range (ATR) | 0.03 | 0.18 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 91.33 | 2.07 |
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
Gauzy Ltd is a fully integrated light and vision control company. Its products include suspended particle device and liquid crystal materials for smart glass applications and AI-powered driver assistance systems, or ADAS, solutions including camera monitoring systems. The company's operating segments are Architecture, Automotive, Safety tech, and Aeronautics. Maximum revenue is generated from its Safety tech segment, which focuses on sales of driver assistance systems for buses, coaches, recreational vehicles, and specific vehicles, such as camera and motion sensor systems, smart mirrors, and safety doors. Geographically, it derives maximum revenue from other European countries (excluding France), followed by the United States, France, Asia, Israel, and other regions.